Epigenetics of cervical cancer. An overview and therapeutic perspectives

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Dueñas González, Alfonso ^a   Lizano, Marcela ^a   Candelaria, Myrna ^b   Cetina, Lucely ^b   Arce, Claudia ^b   Cervera, Eduardo ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APICIDIN; AZACITIDINE; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; BUTYRIC ACID; CYTARABINE; CYTOTOXIC AGENT; DEOXYCYTIDINE; DEPSIPEPTIDE; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROXAMIC ACID DERIVATIVE; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIVALOYLOXYMETHYL BUTYRATE; PROCAINAMIDE; PROCAINE; SODIUM PHENYLBUTYRATE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; DNA METHYLATION; DRUG RESPONSE; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME DEFECT; EPIGENETICS; FATIGUE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; HOST CELL; HUMAN; NEUTROPENIA; NONHUMAN; PREDICTION; PROGNOSIS; PROTEIN MODIFICATION; REVIEW; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; ANIMAL; CANCER STAGING; FEMALE; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; UTERINE CERVIX TUMOR;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HISTONES; HUMANS; NEOPLASM STAGING; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 27744492604     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-4-38     Document Type: Review

References (270)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Richart RM, Barron BA: A follow-up study of patients with cervical displasia. Am J Obstet Gynecol 1969, 105:386-371.
3. Dueñas-Gonzalez A, Cetina L, Mariscal I, de la Garza J: Modern management of locally advanced cervical carcinoma. Cancer Treat Rev 2003, 29:389-399.
4. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999, 17:1339-1348.
5. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ: A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999, 73:177-183.
6. Annual Report on the Results of Treatment in Gynaecological Cancer. J Epidemiol Statist 1998, 3:5-34.
7. Brunschwig A, Daniel W: Evaluation of pelvic exenteration for advanced cancer of the cervix. Surg Gynecol Obstet 1956, 103:337-341.
8. Green JA, Kirwan JM, Tierney JF: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001, 358:781-786.
9. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised tials.
10. López MJ, Spratt JS: Exenterative pelvic surgery. J Surg Oncol 1999, 72:102-114.
11. Hockel M, Knapstein P: The combined operative and radiotherapeutic treatment of recurrent tumors infiltrating the pelvic wall. Gynecol Oncol 1992, 46:20-28.
12. Maneo A, Landoni F, Cormio G, Colombo A, Placa F, Pellegrino A, Mangioni C: Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol 1999, 10:803-807.
13. Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002, 7:342-347.
14. Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E, Barakat RR, Curtin JP: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys 2001, 50:687-694.
15. Hockel M: Laterally extended endopelvic resection: surgical treatment of infrailiac pelvic wall recurrences of gynecological malignancies. Am J Obstet Gynecol 1999, 180:306-312.
16. López-Graniel C, Dolores-Velázquez R, Cetina L, González-Enciso A, Chanona J, Uribe-Domínguez J, Candelaria M, de la Garza J, Dueñas-González A: Pre-exenterative chemotherapy for patients with recurrent cervical cancer patients who do not met the classical criteria for pelvic exenteration. A novel therapeutic approach. BMC Cancer
17. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985, 3:1079-1085.
18. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 2005, 21:4626-4633.
19. zur Hausen: Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999, 111:581-587.
20. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
21. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
22. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987, 61:962-967.
23. Ward P, Coleman DV, Malcolm DB: Regulatory mechanisms of the papillomavirus. Trends Genet 1989, 5:97-99.
24. Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S, Desaintes O: A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res 2004, 64:895-903.
25. Stubenrauch F, Laimins LA: Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 1999, 9:379-386.
26. Stubenrauch F, Zoble T, Iftner T: The E8 domain confers a novel long-distance transcriptional repression activity on the ESE2Cprotein of high-risk human papillomavirus type 31. J Virol 2001, 75:4139-4149.
27. Brown DF, Fan L, Jones J, Bryan J: Colocalization of human papillomavirus type 11 E1 E4 and L1 proteins in human foreskin implants grown in athymic mice. Virology 1994, 201:46-54.
28. Crucius K, Auvinen E, Alonso A: Enhancement of EGF and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997, 15:1437-1444.
29. Munger K, Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 2002, 89:213-228.
30. Howley PM, Scheffner M, Munger K: Oncoproteins encoded by the cancer-associated papillomavirus target the products of retinoblastoma and p53 tumor suppressor genes. Quant Biol 1991, 56:159-155.
31. Henstermann A, Linares LK, Ciechanover A: Complete switch form Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 2001, 98:1218-1223.
32. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001, 20:7874-7887.
33. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
34. Di Leonardo A, Linke SP, Clarkin K, Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994, 8:2540-2551.
35. Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ Jr: Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 1995, 10:1053-1059.
36. Hwang ES, Riese DJ 2nd, Settleman J, Nilson LA, Honig J, Flynn S, DiMaio D: Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. Virology 1993, 67:3720-3729.
37. Southern SA, Herrington CS: Disruption of cell cycle control by human papillomavirus with special reference to cervical carcinoma. Int J Gynecol Cancer 2000, 10:263-274.
38. Doorbar J, Ely S, Sterling J, McLean C, Crawford L: Specific interaction between HPV16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991, 352:824-827.
39. Ueda Y, Enomoto T, Miyatake T, Ozaki K, Yoshizaki T, Kanao H, Ueno Y, Nakashima R, Shroyer KR, Murata Y: Monoclonal expansion with integration of high-risk type human papillomavirus is an essential step for cervical carcinogenesis: association of clonal status and human papillomavirus infection with clinical outcome in cervical intraepithelial neoplasia. Lab Invest 2003, 83:1517-1527.
40. Jablonka E, Lamb MJ: The changing concept of epigenetics. Ann N Y Acad Sci 2002, 981:82-96.
41. Egger G, Liang G, Aparicio A, Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
42. Kawasaki H, Taira K: Transcriptional gene silencing by short interfering RNAs. Curr Opin Mol Ther 2005, 7:125-131.
43. Colot V, Rossignol JL: Eukaryotic DNA methylation as an evolutionary device. Bioessays 1999, 21:402-411.
44. Antequera F, Bird A: CpG islands. EXS 1993, 64:169-185.
45. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 1986, 321:209-213.
46. Antequera F, Bird A: Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 1993, 90:11995-11999.
47. Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003, 33:61-65.
48. Wang KY, James-Shen CK: DNA methyltransferase Dnmt1 and mismatch repair. Oncogene 2004, 23:7898-7902.
49. Okano M, Bell DW, Haber DA, Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methyllation and mammalian development. Cell 1999, 99:247-257.
50. Liu K, Wang YF, Cantemir C, Muller MT: Endogenous assays of DNA methyltransferases: evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol 2003, 23:2709-2719.
51. Reik W, Dean W, Walter J: Epigenetic reprogramming in mammalian development. Science 2001, 293:1089-1093.
52. Zhu WG, Srinivasan K, Dai Z, Duan W, Druhan LJ, Ding H, Yee L, Villalona-Calero MA, Plass C, Otterson GA: Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol 2003, 23:4056-4065.
53. Nguyen CT, Gonzales FA, Jones PA: Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methyllation, MeCP2 binding and acetylation. Nucleic Acids Res 2001, 29:4598-4606.
54. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation- how does it all fit together? Cell Biochem 2002, 87:117-125.
55. Baylin SB: Reversal of gene silencing as a therapeutic target for cancer- roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp 2004, 259:226-233.
56. Bird A: 2002 DNA methylation patterns and epigenetic memory. Genes Dev 2000, 16:6-21.
57. Chakravarthy S, Park YJ, Chodaparambil J, Edayathumangalam RS, Luger K: Structure and dynamic properties of nucleosome core particles. FEBS Lett 2005, 579:895-898.
58. Kuo MH, Allis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20:615-626.
59. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG: Histone acetylation and the cell-cycle in cancer. Front Biosci 2001, 6:D610-D629.
60. Davie JR: Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev 1998, 8:173-178.
61. Trievel RC: Structure and function of histone methyltransferases. Crit Rev Eukaryot Gene Expr 2004, 14:147-169.
62. Daniel JA, Pray-Grant MG, Grant PA: Effector proteins for methylated histones: an expanding family. Cell Cycle 2005, 4: (ahead of print).
63. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T: Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001, 410:116-120.
64. Mahadevan LC, Willis AC, Barratt MJ: Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell 1991, 65:775-783.
65. Nowak SJ, Corces VG: Phosphorylation of histone H3 correlates with transcriptionally active loci. Genes Dev 2000, 14:3003-3013.
66. Pascreau G, Arlot-Bonnemains Y, Prigent C: Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Prog Cell Cycle Res 2003, 5:369-374.
67. Agalioti T, Chen G, Thanos D: Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002, 111:381-392.
68. de la Cruz X, Lois S, Sánchez-Molina S, Martínez-Balbas MA: Do protein motifs read the histone code? Bioessays 2005, 27:164-175.
69. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
70. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a "hot spot" for hypermethyllation in human neoplasia. Proc Natl Acad Sci U S A 1988, 85:5693-5697.
71. Laird PW, Jaenisch R: DNA methyllation and cancer. Hum Molec Genet 1994, 3:1487-1495.
72. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B: Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989, 83:155-158.
73. Santini V, Kantarjian HM, Issa JP: Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134:573-586.
74. Szyf M, Targeti NG: DNA methylation in cancer. Ageing Res Rev 2003, 2:299-328.
75. Bachman KE: Histone modifications and silencing prior to DNA methyllation of a tumor suppressor gene. Cancer Cell 2003, 3:89-95.
76. Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty part? Oncogene 2002, 21:5380-5387.
77. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
78. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988, 48:1159-1161.
79. Ehrlich M: DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. J Nutr 2002, 132:2424S-2429S.
80. Dunn BK: Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003, 983:28-42.
81. Gamma-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M: The 5-methyllcytosine content of DNA from human tumors. Nucleic Acids Res 1983, 11:6883-6894.
82. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
83. Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, Gartler SM: The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 1999, 96:14412-14417.
84. Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB, Ehrlich M: Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998, 77:833-838.
85. Strichman-Almashanu LZ: A genome-wide screen for normally methylated human CgG islands that can identify novel imprinted genes. Genome Res 2002, 12:543-554.
86. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R: Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 2005, 11:1028-1036.
87. Sato N, Maitra A, Fukushima N, Van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C, Goggins M: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003, 63:4158-4166.
88. Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T: Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Pathol 2003, 163:1911-1919.
89. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2 ′-deoxycytidine. Mol Pharmacol 2004, 65:18-27.
90. Koshiishi N, Chong IM, Fukasawa T, Ikeno R, Hayashi Y, Funata N, Nagai H, Miyaki M, Matsumoto Y, Fukayama M: p300 Gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer 2004, 7:85-90.
91. Ward R, Johnson M, Shridhar V, van Deursen J, Couch FJ: CBP truncating mutations in ovarian cancer. J Med Genet 2005, 42:514-518.
92. So CK, Nie Y, Song Y: Loss of heterozygosity and internal tandem duplication mutations of the CBP gene are frequent events in human esophageal squamous cell carcinoma. Clin Cancer Res 2004, 10:19-27.
93. Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, Sakiyama T, Hirama C, Kitabayashi I, Minna JD, Takenoshita S, Yokota J: Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005, 11:512-519.
94. Sobulo OM, Borrow 3, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Doggett NA, Rowley JD, Zeleznik-Le NJ: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997, 94:8732-8777.
95. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ: MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 2000, 28:138-144.
96. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814.
97. Licht JD: AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001, 20:5660-5679.
98. Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG, Licht JD: Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 2002, 22:1804-1818.
99. Verma M: Viral genes and methylation. Ann N Y Acad Sci 2003, 983:170-180.
100. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD: Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002, 11:2091-2102.
101. Tao Q, Robertson KD: Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109:53-63.
102. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 2002, 99:10084-10089.
103. Rosl F, Arab A, Klevenz B, zur Hausen H: The effect of DNA methylation on gene regulation of human papillomaviruses. J Gen Virol 1993, 74:791-801.
104. Badal V, Chuang LS, Tan EH, Badal S, Villa LL, Wheeler CM, Li BF, Bernard HU: CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. Virology 2003, 77:6227-6234.
105. Kalantari M, Calleja-Macías IE, Tewari D, Hagmar B, Lie K, Barrera-Saldaña HA, Wiley DJ, Bernard HU: Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004, 78:12762-12772.
106. Badal S, Badal V, Calleja-Macías IE, Kalantari M, Chuang LS, Li BF, Bernard HU: The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. Virology 2004, 324:483-492.
107. Thain A, Jenkins O, Clarke AR, Gaston K: CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. J Virol 1996, 70:7233-7235.
108. Kim K, Garner-Hamrick PA, Fisher C, Lee D, Lambert PF: Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 2003, 77:12450-12459.
109. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
110. van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R: Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002, 62:2157-2161.
111. Ashkenazi A, Dixit VM: Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999, 11:255-260.
112. Ozoren N, El-Deiry WS: Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003, 13:135-147.
113. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF: Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 2004, 109:786-792.
114. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nature Genet 1997, 17:498-502.
115. Lange T: Activation of telomerase in a human tumor. Proc Natl Acad Sci U S A 1994, 91:2882-2885.
116. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T: Tellomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol 1998, 68:145-149.
117. Nakano N, Watney E, McDougall JK: Telomerase activity and expression of tellomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol 1998, 153:857-864.
118. Snijders PJ, van Duin M, Walboomers JM, Steenbergen RD, Risse EK, Helmerhorst TJ: Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res 1998, 58:3812-3818.
119. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998, 58:1558-1561.
120. Wisman GB, Knol AJ, Helder MN, Krans M, Vries EG, Hollema H: Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 2001, 91:658-664.
121. Guilleret I, Benhattar J: Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 2003, 289:326-334.
122. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M: Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004, 93:407-416.
123. Vousden KH: p53: death star. Cell 2000, 103:691-694.
124. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
125. Melino G, De Laurenzi V, Vousden KH: p73: friend or foe in tumorigenesis. Nature Rev Cancer 2002, 2:605-615.
126. Zhu J, Jiang 3, Zhou W, Chen X: The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998, 58:5061-5065.
127. Yang A, Kaghad M, Wang Y: p63, A p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molec Cell 1998, 2:305-316.
128. Banelli B, Casciano I, Romani M: Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene 2000, 19:4553-4556.
129. Liu SS, Leung RC, Chan KY, Chiu PM, Cheung AN, Tam KF, Ng TY, Wong LC, Ngan HY: p73 Expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res 2004, 10:3309-3316.
130. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G, Murata Y: Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999, 80:458-467.
131. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A 1999, 96:12754-12759.
132. Wong YF, Chung TK, Cheung TH, Nobori T, Yu AL, Yu J, Batova A, Lai KW, Chang AM: Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett 1999, 136:231-235.
133. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty W: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Molec Cancer 2003, 2:24.
134. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001, 7:584-589.
135. Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001, 7:1982-1986.
136. Zambrano P, Segura-Pacheco B, Pérez-Cárdenas E, Cetina L, Revilla-Vázquez A, Taja-Chayeb L, Chávez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Dueñas-González, A. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 2005, 5:44.
137. Uthoff SM, Eichenberger MR, McAuliffe TL, Hamilton CJ, Galandiuk S: Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Molec Carcinogen 2001, 31:56-62.
138. Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002, 34:255-268.
139. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S: Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/ lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001, 153:1161-1174.
140. Giles RH, van Es JH, Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
141. Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO, Lothe RA: Genetic and epigenetic changes of components affecting the WNT pathway in collorectal carcinomas stratified by microsatellite instability. Neoplasia 2005, 7:99-108.
142. Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 2004, 93:621-627.
143. Widschwendter A, Ivarsson L, Blassnig A, Muller HM, Fiegl H, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 2004, 109:163-166.
144. Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB, Lee HP: Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 2005, 96:173-180.
145. Chen CL, Liu SS, Ip SM, Wong LC, Ng TY, Ngan HY: E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer 2003, 39:517-523.
146. Muller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A, Muller-Holzner E, Marth C, Widschwendter M: A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett 2004, 209:231-236.
147. Esteller M, Sparks A, Toyota M, Sánchez-Cespedes M, Capella G, Peinado MA, González S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000, 60:4366-4371.
148. Zysman M, Saka A, Millar A, Knight J, Chapman W, Bapat B: Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002, 62:3663.
149. Pegg AE, Byers TL: Repair of DNA containing 06-alkylguanine. FASEB J 1992, 6:2302-2310.
150. Esteller M, Herman JG: Generating mutations but providing chemosensitivity: the role of 06-methylguanine DNA methyltransferase in human cancer. Oncogene 2004, 23:1-8.
151. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
152. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK: Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001, 92:2760-2768.
153. Qi J, Zhu YQ, Huang MF, Yang D: Hypermethylation of CpG island in 06-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World J Gastroenterol 2005, 11:2022-2025.
154. Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP, Fan CY: 06-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004, 13:967-975.
155. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T: Promoter hypermethylation of the DNA repair gene 06-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003, 13:176-184.
156. Kutler DI, Singh B, Satagopan J: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003, 101:1249-1256.
157. Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. Nature Rev Genet 2001, 2:446-457.
158. D'Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003, 3:23-34.
159. Taniguchi T, Tischkowitz M, Ameziane N: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med 2003, 9:568-574.
160. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004, 23:1000-1004.
161. Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, Gissmann L, Durst M, Pothuri B, Murty VV: Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res 2004, 64:2994-2997.
162. Jass JR: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004, 3:93-100.
163. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B, de la Chapelle A: Replication errors in benign and malignant tumors from hereditary non-polyposis colorectal cancer patients. Cancer Res 1994, 54:1645-1648.
164. Deng G, Chen A, Hong J, Chae HS, Kim YS: Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999, 59:2029-2033.
165. de las Alas MM, Aebi S, Fink D, Howell SB, Los G: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. Natl Cancer Inst 1997, 89:1537-1541.
166. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004, 10:4420-4426.
167. Ciavattini A, Piccioni M, Tranquilli AL, Filosa A, Pieramici T, Goteri G: Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol Res Pract 2005, 201:21-25.
168. Kwasniewska A, Gozdzicka-Jozefiak A, Postawski K, Miturski R: Evaluation of DNA mismatch repair system in cervical dysplasias and invasive carcinomas related to HPV infection. Eur J Gynaecol Oncol 2002, 23:231-235.
169. Chung TK, Cheung TH, Wang VW, Yu MY, Wong YF: Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association. Gynecol Obstet Invest 2001, 52:98-103.
170. Ercoli A, Ferrandina G, Genuardi M, Zannoni GF, Cicchillitti L, Raspaglio G, Carrara S, Mancuso S, Scambia G: Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer. Int J Gynecol Cancer 2005, 15:308-311.
171. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005, 20:645-663.
172. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003, 9:2981-2984.
173. Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, Wilczynski SP, Lerman MI, Pfeifer GP: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 2003, 63:1888-1893.
174. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW, To KF: Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 2003, 105:204-209.
175. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995, 9:15-30.
176. Shohat G, Shani G, Eisenstein M, Kimchi A: The DAP-kinase family of proteins: study of a novel group of calcium-regulated death-promoting kinases. Biochem Biophys Acta 2002, 1600:45-50.
177. Inbal B, Cohen O, Polak-Charcon S, Kopolovic J, Vadai E, Eisenbach L, Kimchi A: DAP kinase links the control of apoptosis to metastasis. Nature 1997, 390:180-184.
178. Watabe K, Ito A, Koma YI, Kitamura Y: IGSF4: a new intercellular adhesion molecule that is called by three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse function. Histol Histopathol 2003, 18:1321-1329.
179. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004, 96:294-305.
180. Li J, Zhang Z, Bidder M, Funk MC, Nguyen L, Goodfellow PJ, Rader IS: IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol 2005, 96:150-158.
181. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, Ahmadian M, Nowak JA, Muller C, Minna JD, Gazdar AF: Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997, 57:3154-3158.
182. Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, Hampton GM: High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res 1997, 57:4082-4090.
183. Hendricks DT, Taylor R, Reed M, Birrer MJ: FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 1997, 57:2112-2115.
184. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J: Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999, 59:5270-5274.
185. Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, Shah KV, Jones RW, Bosch FX, Muñoz N, Cho KR: Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000, 6:3505-3510.
186. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, Mok JE, Muñoz N, Bosch FX, Shah K, Cho KR: Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997, 57:4692-4698.
187. Nakagawa S, Yoshikawa H, Kimura M, Kawana K, Matsumoto K, Onda T, Kino N, Yamada M, Yasugi T, Taketani Y: A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br J Cancer 1999, 79:589-594.
188. Yoshino K, Enomoto T, Nakamura T, Sun H, Ozaki K, Nakashima R, Wada H, Saitoh J, Watanabe Y, Noda K, Murata Y: FHIT alterations in cancerous and non-cancerous cervical epithelium. Int J Cancer 2000, 85:6-13.
189. Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A 2002, 99:3615-3620.
190. Wu Q, Shi H, Suo Z, Nesland IM: 5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol 2003, 27:417-422.
191. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature Genet 2003, 33:197-202.
192. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB: Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 2004, 6:387-398.
193. Chambon P: The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994, 5:115-125.
194. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C: Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000, 92:826-832.
195. Sun SY: Retinoic acid receptor beta and colon cancer. Cancer Biol Ther 2004, 3:87-88.
196. Khan MA, Jenkins GR, Tolleson WH, Creek KE, Pirisi L: Retinoic acid inhibition of human papillomavirus mediated transformation of human keratinocytes. Cancer Res 1993, 53:905-909.
197. Meyskens FL, Surwit E, Moon TE, Childers IM, Davis JR, Dorr RT, Jonson CS, Alberts DS: Enhancement of regression of cervical intraepitheliall neoplasia II (moderate dysplasia) with topically applied all-trans retinoic acid: a randomized trial. J Natl Cancer Inst 1994, 86:539-543.
198. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes Casillas P, Hong WK, Massimini G, Holdener EE, Kazakoff IH: 13-cis-Retinoic acid plus interferon-a2a in locally advanced squamous cell carcinoma of cervix. J Natl Cancer Inst 1993, 85:499-500.
199. Geraddts J, Chen JY, Russell EA, Yankaskas JR, Nieves L, Minna ID: Human cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993, 4:799-809.
200. Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F, Kisseljova N: Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer 2002, 2:4.
201. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB: Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005, 97:273-282.
202. Ivanova T, Vinokurova S, Petrenko A, Eshilev E, Solovyova N, Kisseljov F, Kisseljova N: Frequent hypermethylation of 5′ flanking region of TIMP-2 gene in cervical cancer. Int J Cancer 2004, 108:882-886.
203. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2004, 10:565-571.
204. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 2000, 39:13916-13924.
205. Chan TF, Su TH, Yeh KT, Chang JY, Lin TH, Chen JC, Yuang SS, Chang JG: Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers. Int J Oncol 2003, 23:599-604.
206. Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE, Selhub J, Mason JB: Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994, 74:893-899.
207. Fowler BM, Giuliano AR, Piyathilake C, Nour M, Hatch K: Hypomethylation in cervical tissue: is there a correlation with folate status? Cancer Epidemiol Biomarkers Prev 1998, 7:901-906.
208. de Capoa A, Musolino A, Delia Rosa S, Caiafa P, Mariani L, Del Nonno F, Vocaturo A, Donnorso RP, Niveleau A, Grappelli C: DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol Rep 2003, 10:545-549.
209. Watanabe S, Iwasaka T, Yokoyama M, Uchiyama M, Kaku T, Matsuyama T: Analysis of nuclear chromatin distribution in cervical glandular abnormalities. Acta Cytol 2004, 48:505-513.
210. Bernstein BE, Humphrey EL, Erlich RL, Schneider R, Bouman P, Liu JS, Kouzarides T, Schreiber SL: Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci U S A 2002, 99:8695-8700.
211. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, López JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet 2005, 37:391-400.
212. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
213. Anton M, Horky M, Kuchtickova S, Vojtesek B, Blaha O: Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol 2004, 69:3-6.
214. Vigushin DM, Coombes RC: Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 2004, 4:205-218.
215. Longworth MS, Laimins LA: The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. Virology 2004, 78:3533-3541.
216. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: The E7 oncoprotelin associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999, 18:2449-2458.
217. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ: The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 1999, 73:6209-6219.
218. Bernat A, Massimi P, Banks L: Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J Genet Virol 2002, 83:829-833.
219. Rainier S: Relaxation of imprinted genes in human cancer. Nature 1993, 362:747-749.
220. Ehrlich M: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002, 21:6694-6702.
221. Brown KW, Williams JC, Maitland NJ, Mott MG: Genomic imprinting and the Beckwith-Wiedemann syndrome. Am J Hum Genet 1990, 46, 1000-1001.
222. Douc-Rasy S, Barrois M, Fogel S, Ahomadegbe JC, Sthelin D, Coll, Riou G: High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallellic hypomethylation of H19. Oncogene 1996, 12:423-430.
223. Clarke EA, Anderson TW: Does screening by "Pap" smears help prevent cervical cancer? A case-control study. Lancet 1979, 2:1-4.
224. Fahey MT, Irwing L, Macaskill P: Meta-analysis of pap test accuracy. Am J Epidemiol 1995, 141:680-689.
225. Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E, Gau CH: Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 2005, 97:35-40.
226. Kalof AN, Evans MF, Simmons-Arnold L, Beatty BG, Cooper K: p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol 2005, 29:674-679.
227. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB: Detection of hypermethylated genes in women with and without cervical neoplasia. Natl Cancer Inst 2005, 97:273-282.
228. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46:318-322.
229. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL: Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994, 3:67-71.
230. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M: Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukemia. Br J Haematol 1994, 86:774-779.
231. Anker P, Stroun M: Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test? Clin Chem 2002, 48:1210-1211.
232. Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H, Taja-Chayeb L, García-López P, Segura-Pacheco B, Chávez-Blanco A, Lizano-Soberón M, González-Fierro A, Mariscal I, Wegman-Ostrosky T, Dueñas-González A. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer 2003, 104:663-668.
233. Herman JG: Circulating methylated DNA. Ann N Y Acad Sci 2004, 1022:33-39.
234. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004, 10:1887-1893.
235. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY: Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 2003, 111:887-895.
236. Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, Cheung AN, Ngan HY. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 2004, 93:435-440.
237. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
238. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM: The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 1987. 23:1921-1924.
239. Issa JP: Decitabine. Curr Opin Oncol 2003, 15:446-451.
240. Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW, Johnson PJ, Ambinder RF: Azacytidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 2004, 22:1373-1381.
241. Goffin J, Eisenhauer E: DNA methyltransferase inhibitors- state of the art. Ann Oncol 2002, 13:1699-116.
242. Beaulieu N, Fournel M, Macleod A: Antitumor activity of MG98, an antisense oligonucleotide targeting DNA methyltransferase-1 (DNMT1). [Abstract]. Clin Cancer Res 2001, 7:3800S.
243. Davis AJ, Moore MJ, Gelmon KA: Phase 1 and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, administered as 21-day infusion q4 weekly [Abstract]. Clin Cancer Res 2000, 6:4517S.
244. Segura-Pacheco B, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Mariscal I, Chávez A, Acuña C, Salazar AM, Lizano M, Dueñas-González A: Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 2003, 9:1596-603
245. Angeles E, Vázquez-Valadez VH, Vázquez-Valadez O, Velázquez-Sánchez AM, Ramírez A, Martínez L, Díaz-Barriga S, Romero-Rojas A, Cabrera G, López-Castañares R, Dueñas-González A: Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. Lett Drug Design Discov 2005, 4:282-286.
246. Shao Y, Gao Z, Marks PA, Jiang X: Apoptotic and autophagic cell death induced by histone deacetyllase inhibitors. Proc Natl Acad Sci U S A 2004, 101:18030-18035.
247. Knupfer MM, Pulzer F, Schindler I, Hernaiz Driever P, Knupfer H, Keller E: Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 2001, 21: 347-351
248. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003, 63:7291-7300.
249. Zhang Y, Jung M, Dritschilo A, Jung M: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004, 161:667-674.
250. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528.
251. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
252. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23:3912-3922.
253. Prakash S, Foster BJ, Meyer M, Wozniak A, Hellbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, LoRusso PM: Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 2001, 19:1-11.
254. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004, 45:381-386.
255. Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 2003, 63:2164-2171.
256. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet 1999, 21:103-107.
257. Primeau M, Gagnon J, Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 2003, 103:177-184.
258. Bovenzi V, Momparler RL: Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001, 48:71-76.
259. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 2003, 81:177-186.
260. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA: DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001, 61:1327-1333.
261. Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J: 5-aza-2′-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur J Cancer 1991, 27:216-217.
262. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-161.
263. Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O Jr, Monego E, Rivoire W, Schwartsmann G: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002, 25:496-501.
264. Munster PN, Marchion DC, Bicaku E, Sullivan P, Beam C, Mahany J, Lush R, Sullivan DM, Daud A: Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: a clinical and translational study [Abstract]. Procc ASCO 2005, 24.
265. Chávez-Blanco A, Segura-Pacheco B, Pérez-Cárdenas E, Taja-Chayeb L, Cetina L, Candelaria M, Cantú D, Pérez-Plasencia C, Cabrera G, Trejo-Becerril C, Angeles E, González-Fierro A, García-López P, Zambrano P, Dueñas-González A. Histone acetyllation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Molec Cancer 2005, 4:22.
266. Forrer C, Hofstetter B, Pruschy M, Ciernik IF: Treatment with demethylating agent 5-Aza-2′-Deoxy-Cytidine (DAC) leads to enhanced sensitivity to ionizing radiation (IR) in colorectal carcinoma [Abstract]. Radiat Oncol 2004, 73:S1-S497.
267. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005, 11:4571-4579.
268. Zhang Y, Jung M, Dritschilo A, Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004, 161:667-674.
269. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005, 114:380-386.
270. Chung YL, Wang AJ, Yao LF: Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Molec Cancer Ther 2004, 3:317-325.